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Abstract
Extracellular vesicles (EVs) in human blood are a potential source of biomarkers. To which
extent anticoagulation affects their concentration, cellular origin and protein composition is
largely unexplored. To study this, blood from 23 healthy subjects was collected in acid citrate
dextrose (ACD), citrate or EDTA, or without anticoagulation to obtain serum. EVs were iso-
lated by ultracentrifugation or by size-exclusion chromatography (SEC) for fluorescence-
SEC. EVs were analyzed by micro flow cytometry, NTA, TEM, Western blot, and protein
mass spectrometry. The plasma EV concentration was unaffected by anticoagulants, but
serum contained more platelet EVs. The protein composition of plasma EVs differed between
anticoagulants, and between plasma and serum. Comparison to other studies further
revealed that the shared EV protein composition resembles the “protein corona” of synthetic
nanoparticles incubated in plasma or serum. In conclusion, we have validated a higher con-
centration of platelet EVs in serum than plasma by contemporary EV methods. Anticoagula-
tion should be carefully described (i) to enable study comparison, (ii) to utilize available
sample cohorts, and (iii) when preparing/selecting biobank samples. Further, the similarity of
the EV protein corona and that of nanoparticles implicates that EVs carry both intravesicular
and extravesicular cargo, which will expand their applicability for biomarker discovery.
Introduction
Biomarkers are sought as measurable indicators of pathological processes and for treatment
monitoring. Extracellular vesicles (EVs) contain a rich and multifaceted cargo of proteins,
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metabolites, lipids and nucleic acids for biomarker discovery, and therefore EVs are an excel-
lent source of potential biomarkers. Although EVs can be isolated from all body fluids and
from tissues, blood provides the richest source of EVs. Blood-borne EVs are a heterogeneous
population originating from blood cells, endothelial cells, and for example in cancer patients
from tumor cells [1]. Therefore, blood EVs may well serve as biomarkers of multiple diseases,
either by their concentration or by a selection of molecules derived from their biochemical
composition. So far, the majority of EV biomarker studies have concentrated on the discovery
of cancer biomarkers [2], closely followed by biomarkers for cardiovascular diseases [3].
Plasma and serum samples offer in the form of liquid biopsy a relatively non-invasive means
to detect disease-related biomarkers making them an optimal target for studies using large
study cohorts and biobanks. Unfortunately, most of the currently available biobank samples
have not been collected with EVs in mind. Although some confounders of sample uniformity
such as anticoagulation, agitation and delay in processing (causing ex vivo platelet activation
followed by vesiculation) are becoming better acknowledged, currently many preanalytical
steps remain unaddressed in a systematic way [4, 5]. Recently, the International Society of
Extracellular Vesicles (ISEV) standardization taskforce has realized the urgency of standardiz-
ing blood sample collection and generated harmonization initiatives for the field [6].
So far, only a few studies have addressed the effect of anticoagulation–or its absence i.e. serum
—on the resulting EV population. The seminal study of George et al. demonstrated that the con-
centration of “platelet microparticles”, isolated by centrifugation at 35 000 x g, were higher in
serum than in plasma anticoagulated by acid citrate dextrose (ACD), which was attributed to
platelet activation during clot formation [7]. In the study of Gyo¨rgy et al., ACD was shown to be
superior in comparison to citrate in preventing artefactual platelet activation and vesiculation
during blood collection [5]. However, there are no studies yet on the effect of anticoagulants on
the molecular composition of blood-borne EVs. Therefore, we studied EVs isolated from blood
anticoagulated with the three most commonly used anticoagulants and serum by contemporary
EV analytics and following the latest recommendations regarding blood handling [6, 8].
In pharmaceutics, nanoparticles (NPs) are developed for drug delivery solutions (DDS).
Due to their fast elimination from the body, synthetic NP and their protein corona have
recently been under intensive investigation [9–11]. In addition to DDS applications, NP
corona has also been suggested to be a future diagnostic tool for e.g. cancer diagnostics [12–
14]. Previous studies have shown that the protein corona of NPs can be divided into a hard
and a soft part, depending on the binding affinities of the associating proteins [15–17]. Pro-
teins that bind directly to the surface of the NPs with high affinity, are considered to constitute
the hard corona, and proteins that bind to other proteins via weak protein-protein interac-
tions, constitute the soft corona [18]. The corona of various NPs has been studied in detail,
and a shared “core”proteome has been established, which comprises lipoproteins, complement
and coagulation proteins, and immunoglobulins [19–22]. In the present study we compared
our proteomics results to NP protein corona studies.
Materials and methods
Preparation of plasma and serum
Blood samples were obtained from healthy, fasting volunteers and collected into ACD-A
(Vacuette #455055, Greiner Bio-One, Kremsmu¨nster, Austria), citrate (Vacuette #455322,
Greiner Bio-One), serum (BD #369032, BD Biosciences, Franklin Lakes, USA) and EDTA
(K2F, BD #368861, BD Biosciences) tubes by a protocol approved by the ethical board of Uni-
versity of Helsinki. Volunteers had not used any medication for the previous 7 days and their
informed consent was obtained according to the declaration of Helsinki. Study samples were
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collected twice in Helsinki (set I and II) and once in Budapest (set III), the latter to perform
fluorescence size exclusion chromatography (Flu-SEC). The average age of the donors in set I
was 45 years (range 27–55), 32 years (range 18–51 years) in set II, and 30 years (range 25–36)
in set III. Majority of the volunteers were females (80%, 70%, and 67%). Serum, and ACD, cit-
rate and EDTA plasma were obtained during the same blood collection, 2 x 4 mL or 10 mL for
each plasma/serum type using 18G needle and tourniquet that was released immediately after
the venipuncture, followed by gentle end-over-end mixing 10 times. Blood samples were pro-
cessed within 30 minutes of sampling to obtain plasma, while serum was allowed to clot for 30
minutes at room temperature (RT) prior centrifugation. Samples for set I and II were centri-
fuged twice at 2500 × g for 15 minutes at RT (5804R, Eppendorf AG, Hamburg, Germany).
For the set III, platelet-free plasma and serum was prepared by centrifuging twice at 2500 × g
for 15 minutes at RT (NF 800R, RA 200 swing-out rotor, Nu¨ve, Ankara, Turkey). For the sam-
ple sets I and II, equal volumes of individual donors’ plasma/serum were combined into a pool
of each anticoagulant and serum after the second centrifugation. Pooled plasma/serum sam-
ples were analyzed with Coulter T-540 counter (version 3F, Beckman Coulter, Brea, USA) for
remnant cell counts, and used for experiments directly without freezing. For the set III, indi-
vidual donors’ samples were kept separate for the Flu-SEC analysis. The details of the workflow
are provided in a (S1 Table).
Isolation of EVs
EVs from set I and II were isolated by ultracentrifugation as follows: pooled plasma (ACD, cit-
rate and EDTA), and serum samples were diluted 1:1 with PBS and centrifuged at 110
000 × gmax for 90 minutes at 4˚C (k-factor 190.2, Type 50.2 Ti, Optima-LE 80K, Beckman
Coulter). The supernatant was discarded, and the pellets were resuspended in 20 mL PBS fol-
lowed by re-centrifugation. The final pellet was suspended in 250 μl PBS, aliquoted to Protein
LoBind Tubes (Eppendorf AG) and stored at 4˚C overnight for further analysis, except for
TEM and proteomics for which samples were frozen at -80˚C. For the set III, platelet-free
plasma and serum were purified by SEC on a 3.5 mL gravity column filled with Sepharose CL-
2B gel (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). One mL platelet-free plasma/
serum was loaded on the column, the flow through was discarded and purified EVs were
eluted with 1 mL PBS buffer.
We have submitted all relevant data of our experiments to the EV-TRACK knowledgebase
[23] (http://evtrack.org/, ID: EV190060).
Flow cytometry analysis
Apogee A50 micro flow cytometer (ApogeeFlow, Hertfordshire, UK) equipped with 405 nm
and 488 nm lasers and 525/50 and 575/30 filters was used for measuring EVs. Logarithmic
scale and peak height were used. Event level below 100 events/s with 1.5 μL/minute flow rate
and 150 mbar pressure was considered acceptable for background. Three washing cycles were
performed between the samples. Flow rate was adjusted between 1.5–4.5 μL/minute to keep
average event rates below 3000 events/s. All isolated EV samples were diluted 1:20 to obtain
~1�109 particles/mL and 50 μL was labelled (in technical triplicates) with anti- CD61-PE
(clone VI-PL2, BD Biosciences, 1:25) and anti-CD235a-FITC (clone 11E4B-7-6, BD Biosci-
ences, 1:25), matching isotype antibodies at same dilutions, or with Annexin V–Alexa488
(Invitrogen, Carlsbad, USA, 1:20) in the presence of 5 mM CaCl2. Labelling was done for 1
hour at room temperature in the dark. Before analysis, the isolated EV samples were further
diluted 1:5. Statistical analysis was conducted using Tukey´s multiple comparison test.
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Size exclusion chromatography with on-line fluorescence detection (Flu-
SEC)
Flu-SEC was used to quantify the amount of platelet-derived (CD61+) EVs in serum, and
ACD-, citrate- and EDTA-plasma as described earlier [24]. EVs were separated from soluble
proteins with the Sepharose CL-2B cross-linked agarose gel (GE Healthcare Bio-Sciences AB).
Four μL anti-CD61-PE (clone VI-PL2, 6 μg/mL, BioLegend, USA) was used to label platelet-
derived EVs (technical triplicates) in 100 μL of SEC-isolated plasma/serum. Labelling was per-
formed for 30 minutes at 37 ˚C. Ten μL of labeled sample was injected into a Jasco HPLC sys-
tem (Jasco, Tokyo, Japan) consisting of a PU-2089 pump with a UV-2075 UV/Vis detector
and a FP-2020 fluorescence detector controlled by the Chromnav software v. 1.17.02. Tricorn
5/200 glass columns (GE Healthcare Bio-Sciences AB) were packed with Sepharose CL-2B (GE
Healthcare Bio-Sciences AB), and the eluent of 1 ml of PBS with a flow rate of 0.5 mL/minute.
The fluorescence chromatograms were collected at excitation and emission wavelength corre-
sponding to PE fluorochrome (565/578 nm), and the area under the curve (AUC) of the EV-
peak was used to quantify the amount of platelet-derived EVs in the various plasma and serum
samples. Statistical analysis was conducted using Tukey´s multiple comparison test.
Nanoparticle tracking analysis (NTA)
Particle concentration and size distribution were determined with the NTA instrument
LM14C (NanoSight LTD., London, UK) equipped with blue (404 nm, 70 mW) laser and
sCMOS camera. Settings for data acquisition were: camera level 14, SOP Standard Measure-
ment, autosettings off, polydispersity medium, reproducibility high, and acquisition time 3x
60 sec. The sample dilution was done to 0.1 μm filtered buffer pre-checked for absence of parti-
cles. Each sample was diluted to optimal 40–100 particles/frame concentration for measure-
ment. Data were analyzed with NanoSight NTA 3.0 software with the following settings: auto
background subtraction/blur/minimum track length, and detection threshold 5.
Electron microscopy
Negative staining of whole mounted EV samples was performed as described [25]. Briefly, EVs
were loaded on 200 mesh grids, fixed with 2% PFA, stained with 2% neutral uranyl acetate,
embedded in methyl cellulose uranyl acetate mixture (1.8/0.4%) and viewed with Tecnai 12
(FEI Company, Eindhoven, The Netherland) at 80 kV.
SDS-PAGE and Western blot analysis
Total of 5�1010 particles of all samples were prepared with 6x Laemmli sample buffer with 10%
β-mercaptoethanol and run on 4–20% gradient SDS-PAGE (Mini-Protean TGX Precast pro-
tein gel, Bio-Rad, Hercules, USA). For Western blot analysis, proteins were transferred to
PVDF membrane (Immobilon-P, Merck Millipore, Burlington, USA) at 200 mA for 90 min-
utes using wet transfer. Nonspecific binding was blocked by with 3% BSA in Tris-buffered
saline containing 0.1% Tween-20 (TBST) for 1 hour followed by primary antibody incubation
anti-TSG101 (Clone 51/TSG101 BD Biosciences, 1:500), anti-CD41 (clone SZ22, Beckman
Coulter, 1:2000), or anti-CD9 (clone C-4, Santa Cruz Biotechnology, Dallas, USA, 1:500) over-
night at 4˚C. The membranes were washed three times with TBST followed by incubation with
horseradish peroxidase–conjugated anti-mouse secondary antibody in dilution 1:3000 (GE
Healthcare Bio-Sciences AB). After washing, the signal was detected using Bio-Rad Clarity
Western ECL Substrate (Bio-Rad) and imaged using LAS3000 imaging system (Fuji, Minato,
Japan).
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Mass spectrometry and data analysis
EV pellets corresponding to 100 μg of total protein were adjusted to 25mM Tris, 75mM
NaCl; pH 7.5 and applied to 50 μL of albumin depletion resin slurry (Pierce, Thermo Scien-
tific, Rockform, USA) previously washed with same buffer. Flow through and three washes
were collected by centrifugation and deemed to be albumin-depleted EV proteins. The pro-
tein concentration was measured by bicinchonic acid assay kit (Thermo Fisher Scientific)
for the total protein concentration. Equal amount of protein for each sample was dried in
speed vacuum (Savant, Thermo Fisher Scientific), and then dissolved in 6 M urea and 100
mM Tris-HCl (pH 7.4). Reconstitution was performed with 10 mM of dithiothreitol (DTT)
for 60 minutes at RT, and thereafter 30mM iodoacetamide for 60 minutes in the dark at RT.
Protein digestion was performed with trypsin (18 hour at 37˚C) after the consumption of
abundant iodoacetamide (30 mM DTT, 60 minutes at RT) and 1:10 dilution with high-
purity Milli-Q water (Millipore, Billerica, USA). Finally, the samples were cleaned up with
C18 spin columns, and dried in speed vacuum following the dissolution in 0.1% formic acid
containing 12.5 fmol Hi3 peptide mixture (Waters Corporation, Beverly, USA) per μl. All
procedures were performed according to the manufacturer’s instructions. Liquid chroma-
tography: Four microlitre samples corresponding to 1.4 μg of total protein were injected to
the ultra-performance liquid chromatography (UPLC) system (Waters Corporation) (Dis-
tler et al, 2014). TRIZAIC nanoTile 85 μm x 100mm HSS-T3u wTRAP was applied as a sep-
arating device before mass spectrometry (MS). After loading and trapping, the samples
were washed for 2 minutes at 8.0 μL/minute with 1% buffer B. The analytical gradient was
used as follows: 0–1 minute 1% B; at 2 minutes 5% B; at 65 minutes 30% B; at 78 minutes
50% B; at 80 minutes 85% B; at 83 minutes 85% B; at 84 minutes 1% B; and at 90 minutes
1% B with 450 nL/minute. Buffer A consists of 0.1% formic acid in water and buffer B of
0.1% formic acid in acetonitrile (Sigma-Aldrich). The data was acquired with UDMSE with
Synapt G2-S UDMS (Waters Corporation, Billerica, MA) including ion mobility spectros-
copy (IMS). The data range was 100–2000m/z, scan time 1 s, IMS wave velocity 650ms1.
Calibration was performed by Glu1- fibrinopeptide B MS2 fragments and Glu1- fibrinopep-
tide B precursor ion, used during the acquisitions as a lock mass. Progenesis QI for proteo-
mics software (Version 3, Nonlinear Dynamics) was used for processing of raw files.
Peptide identification was run with Uniprot human FASTA sequences (UniprotKB Release
2015_09, 20205 sequence entries), and label-free protein quantification performed with Hi-
N method (Protein Lynx Global Server) (Silva et al, 2006). The samples were spiked with
12.5 fmol/μL of CLPB_ECOLI (P63285, ClpB protein) peptides (Hi3 E. Coli Standard,
Waters). Digesting reagent was trypsin and 2 miss cleavages were allowed. The peptide
identification parameters were: fixed modification of cysteine (carbamidomethyl) and vari-
able modification of methionine (oxidation). The peptide error tolerance was set to maxi-
mally 10 ppm and the false discovery rate limited to less than 1% and default values (in
Progenesis QI for Proteomics) were used for the rest of the parameters. The quantified pro-
teins in all comparisons were compared by ANOVA on a protein-to-protein basis and their
expression levels were considered significantly different, if ANOVA p-value was less than
0.05. Principal component analysis (PCA), offering the visualization of the main axes of var-
iation in the data groups, was performed by Progenesis QI for proteomics.
Statistics
Statistical analysis of the flu-SEC experiment was performed by using Prism 8 (GraphPad Soft-
ware, LLC, USA). One-way ANOVA test was performed without pairing and assuming Gauss-
ian distribution and equal variance followed by Tukey multiple comparisons test with 95%
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confidence interval. Saphiro-Wilk test was used to test normal distribution, while the Brown–
Forsythe test was used for the equality of group variances. Statistical analysis of flow cytometry
and proteomics experiments was performed with IBM SPSS version 24 (IBM Corp., Armonk,
USA, Released 2016). The data was tested for normality using Saphiro-Wilk test, after which
Kruskall-Wallis non-parametric test was used followed by post-hoc Dunn test. Pearson corre-
lation test was used to examine whether there were correlations between proteins analyzed by
proteomics. The level of significance was set at p� 0.05 in all experiments.
Data repository
The raw files were converted with MSConvert (ProteoWizard) to mzML-files. The mass spec-
trometry proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE (Vizcaino et al 2014) partner repository with the dataset identifier PXD015375.
Results
General characterization of EVs derived from ACD-, citrate- and EDTA-
anticoagulated plasma and serum
In this study, we investigated how different anticoagulants and clotting affect the characteris-
tics of blood-derived EVs. To avoid contamination with any residual platelets and/or residual
platelets generating artificial EVs, all samples were centrifuged within 30 minutes after blood
collection at 2500 × g 15 minutes (twice) as recommended previously [4, 6, 26]. Little or no
residual platelets were detected in the samples (S1A Fig). Particle concentrations and size dis-
tributions were determined with NTA, and the vesicle morphology in samples was confirmed
with TEM. The concentrations of particles calculated per original sample volume of the differ-
ent plasmas or serum were not statistically different in blood collection set I (p = 0.631), but in
set II, some variation was found in EV concentrations between serum and anticoagulated sam-
ples (p = 0.001; S1B Fig). Statistical testing for size distribution of EVs was performed for set II
which had three technical replicates, but essentially similar data was also obtained from sam-
ples of set I with duplicate samples. The analysis revealed statistically significant differences
when measured by bins of size classes. The significant increase of particle counts was seen with
serum-derived EVs that differed from ACD, citrate and EDTA plasma–derived EVs in size
classes 0–100 nm (p = 0.002 (ACD), p = 0.001 (citrate), p = 0.023 (EDTA) and 101–200 nm
p = 0.044 (ACD) (S1C Fig). By TEM, all EVs irrespective of plasma or serum source had a sim-
ilar morphology typically attributed to EVs (S1D Fig). To investigate the protein content of
EVs, equal particle numbers based on NTA were loaded into SDS-PAGE gels. The overall pro-
tein patterns were similar in the ACD- and citrate-derived EV samples, whereas the protein
bands from EDTA- and serum-derived EVs showed visible differences (S1E Fig). In contrast,
typical EV-marker proteins as TSG101 and CD9 were detected at comparable levels when ana-
lyzed by Western blotting (S1F Fig).
Serum and citrate plasma contain increased numbers of platelet-derived
EVs compared to ACD and EDTA plasma samples
In a seminal study of George et al. [7], serum was shown to contain more microparticles i.e.
large EVs than ACD plasma. This prompted us to investigate this claim anew with contempo-
rary analytical methods: EV-dedicated flow cytometry (Apogee 50), flu-SEC and Western blot-
ting. EVs of different plasma and serum samples isolated by ultracentrifugation and
normalized by particle numbers based on NTA, were analyzed with flow cytometry by anti-
CD61 and -CD235a labelling to compare platelet and erythrocyte derived EV proportions in
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plasma and serum, respectively. There were less CD235a+ EVs compared to CD61+ EVs in all
the samples irrespective of the anticoagulant used (Fig 1A). In contrast, more CD61+ events
were detected in the serum samples compared to the ACD (p = 0.006) and EDTA (p = 0.001)
samples, and although there was a similar trend with the citrate sample, it was not statistically
significant. Statistical testing was performed for set II which had three technical replicates, but
essentially similar data was also obtained from samples of set I with duplicate samples.
Annexin V binding to EVs was analyzed to yield information about phosphatidylserine (PS)
expression relevant for procoagulant activity. Staining with (fluorescently-labelled) annexin V
was low in all plasma-derived EV samples compared to serum EVs (Fig 1A). Statistical analysis
showed significant differences (S2 Table) between serum and ACD, citrate, and EDTA EVs
(p = 0.003, p = 0.013, p = 0.006, respectively).
In sample set III, the plasma and serum samples were labelled with anti-CD61 followed by
flu-SEC (Fig 1B). Comparison of the chromatograms of the plasma samples with that of the
serum sample demonstrated that the concentration of CD61+ EVs was significantly increased
in the serum samples compared to ACD, EDTA and citrate plasma (all p<0.001; S3 Table),
even up to 40-fold compared to EDTA. While there was no difference in the concentration of
CD61+ EVs between the EDTA- and ACD plasma samples, citrate-anticoagulated plasma also
had an increased number of CD61+ EVs compared to EDTA (p = 0.046).
When equal particle numbers were loaded on Western blot and probed with anti-CD41 to
detect the platelet glycoprotein IIb, the strongest CD41 signal was in the serum-derived EVs,
followed by the EVs from citrate plasma, whereas in the ACD- and EDTA-derived EVs the
band intensities were equal (Fig 1C). The Western blot, Apogee flow cytometry and Flu-SEC
results confirmed a high concentration of platelet-derived EVs in serum and citrate plasma
compared to the ACD- and EDTA-plasma samples. Finally, also proteomics confirmed an
increase in the presence of CD41 protein in serum and EDTA plasma–derived EV samples
Fig 1. Flow cytometry, fluorescence size exclusion chromatography, and Western blot of extracellular vesicles
isolated from ACD-, citrate-, and EDTA-plasma and serum samples. A) Representative images of the Apogee flow
cytometry analysis with anti-CD61-PE, anti-CD235-FITC and annexin V-FITC, respectively, B)Box blots show the
average of events/μl (n = 3) for the labelled EVs isolated from plasma and serum samples. For the platelet marker
CD61, significant increases in events were detected for serum and citrate-anticoagulated plasma EVs. In contrast,
similar concentrations of erythrocyte (CD235a) EVs were present in plasma and serum. Serum EVs bound more a
Annexin V per EVs compared to plasma EVs, C) representative chromatograms of plasma- and serum-derived EVs
labelled with anti-CD61-PE and characterized with fluorescent size exclusion chromatography (n = 3). EVs were
eluted with the void volume of the column at 2.8 min retention time, and the peak at 6.35 min retention time
corresponded to the unbound antibody. D) The area under the curve values of the first peak were correlated with the
amount of CD61+ EVs in plasma and serum samples. E) probing with anti-CD41 of the Western blots of the plasma
and serum -derived EVs to detect platelet-derived EVs (TSG101 and CD9 are shown in S1 Fig). Each lane was loaded
with a comparable number of particles based on NTA. Asterisks (�) indicates p< 0.05.
https://doi.org/10.1371/journal.pone.0236439.g001
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compared to ACD and citrate plasma -derived EVs (p = 0.04) in the quantitative proteomics of
albumin-depleted samples (Fig 1D).
Protein cargo of the EV corona is modified by anticoagulation or its
absence
Intrigued by the observations of the different protein bands in the SDS gel of the isolated EVs
(S1E Fig), we performed a quantitative proteomic analysis for both albumin-depleted EVs and
non-albumin-depleted EVs isolated from ACD-, citrate-, and EDTA-plasma and serum sam-
ples. In total, 225 proteins were detected from the albumin-depleted and 165 from the non-
depleted EV samples with mass spectrometry Since all identified and quantified proteins (S4
Table) from the non-albumin depleted samples (n = 91 out of 165) were present in the list of
albumin-depleted samples (n = 138 out of 225), we focused on the albumin-depleted prote-
ome. Abundances of the EV proteins were used to perform principal component analysis
(PCA). PCA is available in the Progenesis QI for proteomics—software package. It is an unsu-
pervised method to determine relations between the samples and here we directly used the
imported mass spectrometry data of the reliable proteins identified with two or more unique
peptides. The principal axes of abundance variation are calculated by the software from protein
abundances in the samples. When two or more unique peptide -containing proteins with
p�0.05 ANOVA were plotted in PCA, there was a complete separation of the samples into
four separate groups according to anticoagulation/coagulation (Fig 2). The Pearson’s correla-
tion coefficiency was calculated for the 138 proteins. A threshold for the p-value was set to 0.05
to define statistical significance. More than 80% of protein pairs were positively or negatively
correlated (S5 Table).
The differences in the EV proteomes from plasma and serum samples were quantitative. A
gene ontology analysis was conducted with the FunRich analysis tool [27] using human
genome as background. Of the 138 proteins, 107 were mapped for molecular function, cellular
component and biological process GO terms. The GO terms with p-value�0.05 (Holm-Bon-
ferroni corrected) are shown in Fig 3, and a detailed list of the mapped genes is presented in S6
Table. The most prominent cellular components in GO terms (Fig 3A) were exosomes
(GO:0070062), cytoplasm (GO:0005737) and extracellular (GO:0005576) comprising 77.7%,
68.0% and 66.0% of the identified proteins, respectively. The enriched biological process GO
terms (Fig 3B) were cell growth and/or maintenance (GO:0016049) and immune response
(GO:0006955), comprising 32.4% and 22.5%, respectively. For the molecular function (Fig 3C)
Fig 2. Principal component analysis (PCA) of protein quantification data with two or more unique peptide
-containing proteins with ANOVA significance p�0.05. Green: citrate; blue: ACD; red: EDTA; yellow: serum. Each
sample was run in triplicates.
https://doi.org/10.1371/journal.pone.0236439.g002
PLOS ONE External cargo of blood-derived extracellular vesicles—Implications for biomarker discovery
PLOS ONE | https://doi.org/10.1371/journal.pone.0236439 August 19, 2020 8 / 19
enriched GO terms were transporter activity (GO:0005215), structural constituent of cytoskel-
eton (GO:0005200), structural molecule activity (GO:0005198), and complement activity (GO:
0006956) comprising 14.7%, 14.7%, 11.8%, and 10.8% of the identified proteins, respectively.
Of the 138 proteins, 35 showed significant differences in concentration (ANOVA with
Kruskall-Wallis test followed by Dunn´s test), between the plasma and serum EV samples
(Table 1). The majority of these proteins [21] were upregulated in the EVs isolated from
serum, 12 proteins in the EVs isolated from EDTA-plasma, and two in the EVs isolated from
ACD-plasma. The further analysis of 21 proteins with highest mean in serum EVs revealed
enriched molecular function in transporter activity (GO:0005215), including apolipoproteins
A1, A2 and C3, transferrin and vitamin D binding protein. Additionally, the EVs displayed dif-
ferences in the amounts of coagulation and complement proteins, protease inhibitors and dif-
ferent classes of immunoglobulins (Table 1). The most prominent GO term in molecular
function of combined EDTA and ACD plasma EVs was protein binding (GO:0005515).
The proteome of plasma EVs has been reported in several studies and can be obtained from
Exocarta [28] and EVpedia [29]. To understand our results, we performed data comparisons
between our results and the results from two other studies which we deemed most relevant by
their study design. The study of Kalra et al. compared the proteome of plasma EVs which had
been isolated with three different isolation methods: differential ultracentrifugation (dUC),
immunoaffinity, and discontinuous gradient ultracentrifugation (DG) [30]. This study
reported 56 common proteins with our proteome from dUC and DG samples, including com-
plement proteins, immunoglobulins, apolipoproteins and keratins. Similar results have also
been reported in studies using dUC [31–34] or SEC as isolation method [35–37]. In the study
of Karimi et al. it was shown that by combining dUC, DG and SEC, it is possible to avoid lipo-
protein and soluble protein contamination and to isolate highly purified plasma EVs for prote-
omic analysis [36]. Comparing our 138 proteins from UC-isolated EVs with those of dUC-
isolated EVs [30] and dUC combined with DG and followed by SEC isolated EVs [36] showed
that 46 proteins were shared with both of the other data sets, 9 proteins only with Kalra et al.
and 53 proteins only with Karimi et al. (Fig 4).
Fig 3. Gene ontology enrichment analysis of identified proteins from EVs with two or more unique peptide–
containing proteins and p-value�0.05 (Holm-Bonferroni corrected) performed with FunRich 2.1.2 software
using human genome as a background. A) Cellular component enrichment analysis, B) molecular function
enrichment analysis, and C) biological process enrichment analysis.
https://doi.org/10.1371/journal.pone.0236439.g003
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Table 1. Proteins (n = 35) showing significant difference between the plasma and serum EV samples (Anova with Kruskall-Wallis test followed by Dunn´s test, p-
value� 0.05) are shown. Five keratins listed here were not excluded although they are considered to originate from exogenous sources such as skin or hair.
Kruskall-Wallis
Group Mean SD ACD Citrate EDTA
p-value p-value p-value
Alpha-1-antitrypsin Citrate 21128.5 3673.3 0.174
EDTA 57249.3 23861.6 0.571 0.054
Serum 84532.5 5897.2 0.141 0.005� 0.365
APOC4-APOC2 readthrough (NMD candidate) Citrate 2899.5 269.1 0.308
EDTA 14746.6 3666.4 0.308 0.042�
Serum 23054.3 322.9 0.042� 0.002� 0.308
Apolipoprotein A-I Citrate 327405.2 26276.5 0.571
EDTA 763780.0 136205.2 0.174 0.054
Serum 964279.7 111475.8 0.031� 0.007� 0.428
Apolipoprotein A-II Citrate 9432.0 1918.8 0.428
EDTA 32012.0 10122.1 0.213 0.042�
Serum 46145.7 3288.2 0.042� 0.005� 0.428
Apolipoprotein C-III Citrate 12313.4 2369.5 0.734
EDTA 45020.7 29899.0 0.089 0.042�
Serum 40119.1 2971.9 0.042� 0.017� 0.734
C4b-binding protein beta chain Citrate 32830.5 4683.5 0.308
EDTA 145233.1 92104.5 0.174 0.017�
Serum 129147.1 21501.1 0.089 0.007� 0.734
Clusterin Citrate 15921.9 2556.5 0.174
EDTA 64159.9 2776.6 0.113 0.003�
Serum 26015. 4840.8 1.00 0.174 0.113
Complement C1s subcomponent Citrate 130601.2 18724.9 0.308
EDTA 77030.6 18048.8 0.042� 0.308
Serum 574764.3 80460.7 0.308 0.042� 0.002�
Complement factor H Citrate 37145.7 4413.8 0.571
EDTA 97696.5 24032.5 0.213 0.07
Serum 161619.3 19798.8 0.024� 0.005� 0.308
Extracellular matrix protein 1 Citrate 1361.0 349.4 0.910
EDTA 2848.3 764.6 0.113 0.141
Serum 7871.9 5854.9 0.009� 0.013� 0.3008
Far upstream element-binding protein 2 Citrate 40731.4 11563.2 0.428
EDTA 130437.5 10503.6 0.428 0.113
Serum 272062.8 40803.3 0.042� 0.005� 0.213
Fibrinogen alpha chain Citrate 286470.0 80015.7 0.497
EDTA 1040565.0 140516.8 0.213 0.054
Serum 178365.8 33284.6 0.089 0.308 0.003�
Fibrinogen beta chain Citrate 247084.9 82918.2 0.571
EDTA 796061.9 71036.9 0.213 0.07
Serum 52282.2 24865.0 0.07 0.213 0.002�
Fibrinogen gamma chain Citrate 214132.6 59581.7 0.428
EDTA 681749.2 115693.1 0.428 0.113
Serum 112276.9 6000.7 0.042� 0.213 0.005�
(Continued)
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Table 1. (Continued)
Kruskall-Wallis
Group Mean SD ACD Citrate EDTA
p-value p-value p-value
Ficolin-3 Citrate 39691.6 6389.57 0.571
EDTA 3262480.8 16914469 0.024� 0.005�
Serum 175056.8 89930.4 0.213 0.07 0.308
Haptoglobin-related protein Citrate 72310.9 6719.7 0.005�
EDTA 216281.3 208441.5 0.308 0.07
Serum 121909.9 24163.3 0.174 0.141 0.734
Immunoglobulin heavy variable 5–51 Citrate 2005.0 146.1 0.089
EDTA 27441.8 12458.0 0.174 0.002�
Serum 3673.2 79.9 0.734 0.174 0.089
Immunoglobulin kappa variable 3–20 Citrate 23823.5 1779.9 0.571
EDTA 79664.0 33562.0 0.024� 0.005�
Serum 46655.7 3347.3 0.213 0.07 0.308
Immunoglobulin lambda constant 2 Citrate 34925.7 9817.4 0.365
EDTA 90591.5 19342.8 0.365 0.07
Serum 145174.1 28041.9 0.042� 0.003� 0.258
Immunoglobulin lambda constant 7 Citrate 3043.6 1419.7 0.428
EDTA 1933.9 501.0 0.213 0.651
Serum 438.4 349.6 0.007� 0.054 0.141
Immunoglobulin lambda variable 2–14 Citrate 11752.6 3612.3 0.910
EDTA 21819.8 4915.8 0.054 0.07
Serum 23822.8 8356.2 0.024� 0.031� 0.734
Immunoglobulin lambda-like polypeptide 5 Citrate 67358.0 15634.6 0.428
EDTA 186777.2 68310.8 0.113 0.017�
Serum 164633.0 4839.5 0.089 0.013� 0.91
Inter-alpha-trypsin inhibitor heavy chain H4 Citrate 2136.6 130.5 0.910
EDTA 4742.3 2796.6 0.141 0.113
Serum 27310.24 1537.1 0.013� 0.009� 0.308
Keratin type II cuticular Hb6 Citrate 4676.76 1131.9 0.571
EDTA 226331.9 72476.3 0.005� 0.024�
Serum 9422.9 332.7 0.07 0.231 0.308
Keratin type II cytoskeletal 1b Citrate 6686.7 1671.8 0.571
EDTA 23137.7 6736.6 0.089 0.024�
Serum 25899.7 3549.7 0.07 0.017� 0.91
Keratin type II cytoskeletal 3 Citrate 8968.3 1474.3 1.00
EDTA 16936.0 5221.0 0.571 0.089
Serum 25805.0 3225.4 0.089 0.005� 0.258
Keratin type II cytoskeletal 7 Citrate 9786.3 5026.1 0.428
EDTA 28739.1 9806.1 0.428 0.113
Serum 78335.4 27832.8 0.042� 0.005� 0.213
Keratin type II cytoskeletal 75 Citrate 17435.1 3417.5 0.910
EDTA 23954.2 5558.9 0.231 0.258
Serum 39640.8 7021.8 0.013� 0.017� 0.213
Mannan-binding lectin serine protease 1 Citrate 19359.2 838.0 1.00
EDTA 369877.9 451573.1 0.089 0.005�
Serum 82930.6 47213.7 0.308 0.031� 0.497
(Continued)
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Because we found similarities in the EV proteome of our study with these two previous
studies, which had used different and more diligent EV isolation procedures, we hypothesized
that there may be a shared “EV protein corona”. To investigate this hypothesis, we compared
Table 1. (Continued)
Kruskall-Wallis
Group Mean SD ACD Citrate EDTA
p-value p-value p-value
NFX1-type zinc finger-containing protein 1 Citrate 1665.6 406.6 0.258
EDTA 5768.4 2119.3 0.365 0.042�
Serum 9485.0 2649.1 0.07 0.003� 0.365
Pro-thrombin Citrate 16532.6 2078.7 0.174
EDTA 36920.9 16154.9 1.00 0.174
Serum 92027.3 11207.8 0.113 0.003� 0.113
Putative uncharacterized protein MYH16 Citrate 393.4 93.2 0.734
EDTA 5638.6 2475.0 0.024� 0.009�
Serum 734.2 125.3 0.308 0.174 0.213
Serotransferrin Citrate 246039.8 45043.8 0.428
EDTA 603798.7 62743.3 0.258 0.054
Serum 1127260.8 200381.7 0.031� 0.003� 0.308�
Transthyretin Citrate 850.2 268.5 0.024�
EDTA 5663.8 5519.4 1.00 0.024�
Serum 1237.8 259.7 0.113 0.497 0.113
Vitamin D-binding protein Citrate 11973.0 1888.2 0.497
EDTA 43094.2 16511.6 0.258 0.07
Serum 79524.5 15148.7 0.042� 0.007� 0.365
https://doi.org/10.1371/journal.pone.0236439.t001
Fig 4. Venn diagram of overlapping proteins from a comparison of the proteomic data of our study and two
previous studies of proteome of EVs [30, 36].
https://doi.org/10.1371/journal.pone.0236439.g004
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our EV proteome to that of NPs, which had been incubated with plasma to generate a protein
corona. We compared the list of the 108 proteins which were shared with our study and two
previous EV studies, assuming that these proteins belonged to the EV protein corona, to a set
of 84 proteins which were shared between two previous NP proteomic studies [22, 38]. Kari
et al. used multi-parametric surface plasmon resonance to identify hard and soft protein
corona of liposomes in situ [38], and Weber et al. analyzed the polystyrene NP protein corona
after isolation by dUC and asymmetric flow field-flow fractionation [22]. In total, 89 of the
“EV corona proteins” were identical to those reported to belong to the NP corona proteins
(65%; Fig 5). A gene ontology analysis with the FunRich analysis tool [27] using human
genome as background enabled us to map 73 proteins (out of the 89 common proteins) for
molecular function, cellular component and biological process GO terms (S6 Table). The most
prominent cellular component GO terms were exosomes (GO:0070062), extracellular
(GO:0005576) and cytoplasm (GO: 0005737) comprising 86%, 75% and 63% of the identified
proteins, respectively. The enriched biological process GO terms were cell growth and/or
maintenance (GO:0016049), immune response (GO:0006955) and transport (GO: 0006810)
comprising 32%, 30% and 20%, respectively. For the molecular function enriched GO terms
were transporter activity (GO:0005215), structural constituent of cytoskeleton (GO:0005200)
and complement activity (GO: 0006956), comprising 20%, 17% and 14% of the identified pro-
teins, respectively.
Discussion
At present, blood-derived EVs are a potential source for new biomarkers. Since a blood sample
is an ex vivo sample, the impact of the pre-analytical choices prior to EV isolation needs to be
Fig 5. Venn diagram comparing the proteomic data of our study to a shared proteome from two previous studies of
nanoparticle corona proteins accumulated from plasma [22, 38] showing a set of overlapping proteins, which
suggests that a common corona proteome of plasma proteins accumulates on EVs and synthetic particles [22, 38].
https://doi.org/10.1371/journal.pone.0236439.g005
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accounted for to make intelligent use of high-throughput data utilizing samples of large
cohorts and biobanks. Therefore, we compared EVs isolated from ACD-, citrate and EDTA-
plasma, and serum, to investigate the effects of anticoagulation on the cellular origin and pro-
tein composition of the isolated EVs. An early study by George et al. compared large EVs from
plasma and serum, and they showed that serum contained more platelet-derived microparti-
cles than ACD plasma [7]. Because their study disregarded a large bulk of EVs, we readdressed
this issue with contemporary analytical EV methodologies. We showed with four different
methods that the serum samples indeed contain a significantly higher concentration of plate-
let-derived EVs than the plasma samples, and that the serum-derived EVs bound more
Annexin V. The number of platelet-derived EVs was also increased in citrate plasma compared
to ACD and EDTA, which confirms previous results [39]. This suggests that citrate inhibits
platelet activation less efficiently than ACD and EDTA, which results in generation platelet-
derived EVs in blood samples during and after blood collection, especially if there is a delay
between the sample collection and processing. This is significant, because uncontrolled release
of platelet-derived EVs affects biomarker discovery, e.g., platelet-derived EVs were shown to
skew the miRNA populations in patient and control samples [40]. Although the total concen-
tration and size distribution of the plasma-derived EVs were essentially similar between the
various anticoagulated plasma and serum samples, a slight difference in the particle numbers
was observed between sample sets I and II, where in set II, the concentration of serum-derived
EVs was higher than in plasma. This difference may be explained by the variation between the
donor pools, and one of the limitations of this study was that the EV analyses could not be
associated to the individual donor characteristics such as age or gender So far, very few studies
have addressed how such factors impact the EV concentrations in healthy populations [41–
43]. However, the use of large, well-prepared sample pools enabled us to apply the same mate-
rial systematically in multiple analyses, strengthening the comparison of the results between
analytics.
Ultracentrifugation is still the most used method for EV isolation from plasma (>60%) or
serum (>55%) reported in EV-TRACK (http://evtrack.org/, accessed 20.01.2020), although
other methods e.g. SEC and density gradient ultracentrifugation have been adopted. Thus, to
mimic the situation with most studies, the isolation of EVs in this study was performed with
dUC with one washing step, except Flu-SEC. The use of dUC is another limitation of this
study, because dUC is known to co-isolate protein aggregates and lipoproteins [44, 45]. Addi-
tionally, the recovery of EVs with dUC is variable (10–80%) and often low [46] and it excludes
the smallest of EVs and exomeres, to which little attention has been focused so far [47, 48].
Thus, this study did not address the possible alterations in the smallest EV subpopulations.
Several studies of proteomics on plasma and/or serum-derived EVs using various isolation
methods have been published [32, 34–37], and regardless of the isolation method, the pub-
lished EV proteomes show a remarkable similarity. This indicates that certain plasma proteins
are tightly bound to the EV surface constituting a true protein corona rather than being mere
co-isolating contaminants. The proteome of EVs comprised lipoproteins, immunoglobulins,
and coagulation and complement proteins. The presence of several transporter proteins in the
protein corona suggests that EV surfaces may have a previously unconsidered role in biomole-
cule transportation. As the enzymatic removal of the EV surface proteins has been shown to
hamper cellular uptake [49, 50], the protein corona may affect the functional properties of
EVs. The heterogeneity of the protein corona was shown to affect the hydrodynamic range of
EVs, as well as their mobility in solution and extracellular matrix [51].
Our proteomics analysis of the albumin-depleted EVs from plasma and serum showed an
overlap not only with the previous EV studies [30, 36], but also with NP studies [22, 38]. The
NP studies chosen for comparison applied isolation methods asymmetric field flow
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fractionation and multi-parametric surface plasmon resonance which are considered not to
co-isolate soluble proteins, and thereby strengthen the concept that the shared proteins with
EVs are unlikely to be co-isolated—artefacts. Of note, in some corona studies NPs added to
plasma were isolated by methods which are also used to isolate EVs from plasma and serum
[52–56]. In such studies, one cannot conclude whether the reported protein corona of NPs
originates truly from NPs, from co-isolated EVs, or both. In future studies, this aspect should
be taken into account when conducting NP protein corona research, as also noted by a recent
viewpoint article [57].
The similarities between the shared extravesicular cargo of EVs and NPs imply that both
EVs and NPs accumulate a selected plasma protein corona on their surface, which may be
applicable to biomarker discovery. Many of the surface-attached proteins of EVs associate with
pathological states and thus could be useful for diagnostics. For example, synovial fluid-
derived EVs of rheumatic arthritis patients were shown to carry complement factors and com-
plement activator molecules [58], and the adhered protein composition of EVs was shown to
reflect the disease state in preeclampsia [59].
To our knowledge, this is the first study highlighting the importance of the EV corona. To
conclude, we state that plasma obtained with different anticoagulant and/or serum should not
be mixed as a source of EVs for biomarker discovery. This is particularly relevant for clinical
studies and biobank samples. Secondly, an enrichment of platelet-derived EVs from serum
samples may offer new opportunities to study platelet-associated pathologies. Thirdly, the
comparison of proteomic studies suggests that EVs have a protein corona that includes both
soft and hard coronas offering an interactive surface with biological membranes, which may
offer novel insights in the pathophysiological roles of EVs. Since the investigations on the com-
municasome role of EVs have so far predominantly concentrated on the intravesicular cargo
and regarded the corona proteins simply as contaminants, we suggest that this “piggyback”
cargo should be re-evaluated. We expect our study to pave a way for more discoveries regard-
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